A Phase IIa, 3 Strata Dose-Defining Study Evaluating the Hemodynamic Effects, Safety and Tolerability of CXL-1020 in Patients With Systolic Heart Failure.
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2016
At a glance
- Drugs CXL 1020 (Primary)
- Indications Heart failure
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Cardioxyl Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 13 Apr 2012 Actual patient number (69) added as reported by ClinicalTrials.gov.
- 13 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.